Less than four months after going public and being valued at more than $3 billion by Wall Street, Zymergen Inc. unleashed some bad news Tuesday afternoon, and was on pace to lose more than two-thirds ...

Jason Kelly, PhD, CEO and co-founder of Ginkgo Bioworks Nearly a year since a retreat from rosy revenue projections that led to its CEO quitting and its stock nearly collapsing, Zymergen has found a ...

Ginkgo Bioworks cofounders Jason Kelly and Reshma Shetty ranked No. 5 on the 2022 Tech Power Players 50. See the full list here. Boston-based Ginkgo Bioworks has agreed to buy Zymergen, a biotech firm ...

Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, marking the final act in Zymergen’s dramatic and brisk fall from grace. Signage is ...

EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation ...

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (ZY), today reported preliminary financial results for the first quarter ended March 31, 2022. “Our mission at ...

Arguably the most groundbreaking company among recent IPOs (IPO), Zymergen specializes in synthetic biology. Specifically, this technology firm uses nature as a canvas, inspiring a range of disparate ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Following a $575 million IPO in April, the company's once ...

Zymergen's lock-up period expires at a time when it's unsure about its products pipeline and target market. Zymergen shares listed in April via an initial public offering (IPO), with shares rocketing ...